Abstract | BACKGROUND: METHODS AND RESULTS: In a randomized, placebo-controlled design, 16 healthy male subjects received either a single subcutaneous dose of fondaparinux (10 mg) and a single intravenous bolus of rFVIIa (90 microg/kg; n=8), fondaparinux and placebo (n=4), or placebo and rFVIIa (n=4). Fondaparinux (or placebo) was administered 2 hours before rFVIIa (or placebo). Injection of rFVIIa after fondaparinux normalized the prolonged activated partial thromboplastin and prothrombin times and reversed the decrease in prothrombin activation fragments 1+2 (F(1+2)), as observed with fondaparinux alone. Thrombin-generation time and endogenous thrombin potential, which were inhibited by fondaparinux, normalized up to 6 hours after rFVIIa injection. CONCLUSIONS:
|
Authors | Nick R Bijsterveld, Arno H Moons, S Matthijs Boekholdt, Benien E van Aken, Hein Fennema, Ron J G Peters, Joost C M Meijers, Harry R Büller, Marcel Levi |
Journal | Circulation
(Circulation)
Vol. 106
Issue 20
Pg. 2550-4
(Nov 12 2002)
ISSN: 1524-4539 [Electronic] United States |
PMID | 12427650
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticoagulants
- Polysaccharides
- Recombinant Proteins
- Factor VII
- Factor VIIa
- Thrombin
- Fondaparinux
|
Topics |
- Adolescent
- Adult
- Anticoagulants
(antagonists & inhibitors, blood)
- Blood Coagulation
- Double-Blind Method
- Factor VII
(analysis)
- Factor VIIa
(genetics, pharmacology)
- Fondaparinux
- Humans
- Kinetics
- Male
- Middle Aged
- Polysaccharides
(antagonists & inhibitors, blood)
- Recombinant Proteins
(pharmacology)
- Thrombin
(metabolism)
- Thrombin Time
|